Berlin - Delayed Quote EUR

Aurinia Pharmaceuticals Inc (IKAP.BE)

Compare

8.59

-0.03

(-0.32%)

At close: December 23 at 8:13:02 AM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for IKAP.BE

Exploring Three High Growth Tech Stocks In The United States

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aurinia Pharmaceuticals Inc (IKAP.BE)

Comparisons

Indicators

Technicals

Corporate Events

-5.14%

2.09%

64.38%

6.76%

3.67%

-51.17%

1,356.61%

Recent News: IKAP.BE

Exploring Three High Growth Tech Stocks In The United States

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets

Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates

Aurinia: Q3 Earnings Snapshot

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth